Carlos Narvaez1, Steven E Schild2, Dirk Rades3. 1. Department of Radiation Oncology, University of Lübeck, Lübeck, Germany. 2. Department of Radiation Oncology, Mayo Clinic, Scottsdale, AZ, U.S.A. 3. Department of Radiation Oncology, University of Lübeck, Lübeck, Germany; rades.dirk@gmx.net.
Abstract
BACKGROUND/AIM: Some patients with unresectable or incompletely resected head-and-neck cancer (SCCHN) cannot tolerate radiochemotherapy. Alternatives are needed that are more effective than conventional radiotherapy alone. PATIENTS AND METHODS: This retrospective study investigated patients irradiated for non-metastatic stage IV SCCHN who could not receive concurrent chemotherapy. Eight patients received accelerated radiotherapy with concomitant boost (group A) and 31 patients conventionally fractionated radiotherapy (group B). Groups were matched for tumor site, gender, age, performance score and histologic grade. RESULTS: Two-year PFS-rates were 63% in group A vs. 41% in group B, and median PFS-times were 36 vs. 10 months (p=0.48). Two-year OS-rates were 88% vs. 37%, and median OS-times were 44 vs. 14 months (p=0.19). Grade ≥2 radiation dermatitis was significantly (p=0.040) more common in group B; other toxicities were similar. CONCLUSION: Accelerated fractionation with concomitant boost appeared superior to conventional fractionation and can be considered for patients with stage IV SCCHN not suitable for radiochemotherapy. Larger studies are needed to confirm these findings. Copyright
BACKGROUND/AIM: Some patients with unresectable or incompletely resected head-and-neck cancer (SCCHN) cannot tolerate radiochemotherapy. Alternatives are needed that are more effective than conventional radiotherapy alone. PATIENTS AND METHODS: This retrospective study investigated patients irradiated for non-metastatic stage IV SCCHN who could not receive concurrent chemotherapy. Eight patients received accelerated radiotherapy with concomitant boost (group A) and 31 patients conventionally fractionated radiotherapy (group B). Groups were matched for tumor site, gender, age, performance score and histologic grade. RESULTS: Two-year PFS-rates were 63% in group A vs. 41% in group B, and median PFS-times were 36 vs. 10 months (p=0.48). Two-year OS-rates were 88% vs. 37%, and median OS-times were 44 vs. 14 months (p=0.19). Grade ≥2 radiation dermatitis was significantly (p=0.040) more common in group B; other toxicities were similar. CONCLUSION: Accelerated fractionation with concomitant boost appeared superior to conventional fractionation and can be considered for patients with stage IV SCCHN not suitable for radiochemotherapy. Larger studies are needed to confirm these findings. Copyright
Authors: Benjamin Lacas; Jean Bourhis; Jens Overgaard; Qiang Zhang; Vincent Grégoire; Matthew Nankivell; Björn Zackrisson; Zbigniew Szutkowski; Rafał Suwiński; Michael Poulsen; Brian O'Sullivan; Renzo Corvò; Sarbani Ghosh Laskar; Carlo Fallai; Hideya Yamazaki; Werner Dobrowsky; Kwan Ho Cho; Beth Beadle; Johannes A Langendijk; Celia Maria Pais Viegas; John Hay; Mohamed Lotayef; Mahesh K B Parmar; Anne Aupérin; Carla van Herpen; Philippe Maingon; Andy M Trotti; Cai Grau; Jean-Pierre Pignon; Pierre Blanchard Journal: Lancet Oncol Date: 2017-07-27 Impact factor: 41.316
Authors: Jay S Cooper; Qiang Zhang; Thomas F Pajak; Arlene A Forastiere; John Jacobs; Scott B Saxman; Julie A Kish; Harold E Kim; Anthony J Cmelak; Marvin Rotman; Robert Lustig; John F Ensley; Wade Thorstad; Christopher J Schultz; Sue S Yom; K Kian Ang Journal: Int J Radiat Oncol Biol Phys Date: 2012-06-30 Impact factor: 7.038
Authors: S Staar; V Rudat; H Stuetzer; A Dietz; P Volling; M Schroeder; M Flentje; H E Eckel; R P Mueller Journal: Int J Radiat Oncol Biol Phys Date: 2001-08-01 Impact factor: 7.038
Authors: Gokoulakrichenane Loganadane; Benjamin H Kann; Henry S Park; Skyler B Johnson; Saral Mehra; Benjamin L Judson; Aarti Bhatia; Yazid Belkacemi; Wendell G Yarbrough; Barbara Burtness; Zain A Husain Journal: Anticancer Res Date: 2019-09 Impact factor: 2.480
Authors: D J Adelstein; P Lavertu; J P Saxton; M Secic; B G Wood; J R Wanamaker; I Eliachar; M Strome; M A Larto Journal: Cancer Date: 2000-02-15 Impact factor: 6.860
Authors: Jacques Bernier; Jay S Cooper; T F Pajak; M van Glabbeke; J Bourhis; Arlene Forastiere; Esat Mahmut Ozsahin; John R Jacobs; J Jassem; Kie-Kian Ang; J L Lefèbvre Journal: Head Neck Date: 2005-10 Impact factor: 3.147
Authors: Arlene A Forastiere; Qiang Zhang; Randal S Weber; Moshe H Maor; Helmuth Goepfert; Thomas F Pajak; William Morrison; Bonnie Glisson; Andy Trotti; John A Ridge; Wade Thorstad; Henry Wagner; John F Ensley; Jay S Cooper Journal: J Clin Oncol Date: 2012-11-26 Impact factor: 44.544
Authors: Dirk Rades; Britta Warwas; Karsten Gerull; Ralph Pries; Anke Leichtle; Karl L Bruchhage; Samer G Hakim; Steven E Schild; Florian Cremers Journal: In Vivo Date: 2022 Jul-Aug Impact factor: 2.406
Authors: Franco Ionna; Paolo Bossi; Agostino Guida; Andrea Alberti; Paolo Muto; Giovanni Salzano; Alessandro Ottaiano; Fabio Maglitto; Davide Leopardo; Marco De Felice; Francesco Longo; Salvatore Tafuto; Giuseppina Della Vittoria Scarpati; Francesco Perri Journal: Cancers (Basel) Date: 2021-05-14 Impact factor: 6.639